Article Contents ::
- 1 The Brand Name ABAVIR Has Generic Salt :: ABACAVIR
- 2 ABAVIR Is From Company HETERO HC. Priced :: Rs. 1410
- 3 ABAVIR have ABACAVIR is comes under Sub class Anti Retrovirals (Drugs for HIV) of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Anti Retrovirals (Drugs for HIV)
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ABAVIR Has Generic Salt :: ABACAVIR
ABAVIR Is From Company HETERO HC. Priced :: Rs. 1410
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
ABACAVIR | TAB | Rs. 1410 | 30 |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 30 |
ABAVIR | HETERO HC. | 300MG | 30 | Rs. 1410 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From HETERO HC. :: ABAVIR | ABACAVIR | Anti Infectives | Anti Retrovirals (Drugs for HIV) |
Indications for Drugs ::
Acquired immunodeficiency syndrome (AIDS)
Drug Dose ::
Adults and Adolescents >12 years: Recommended Dose: 1 tablet twice daily. This should not be administered to adolescents and adults who weigh <40 kg because it is a fixed-dose tablet, therefore the dose cannot be reduced. Renal Impairment: Dosage reduction of lamivudine or zidovudine may be necessary in renally impaired patients. It is therefore recommended that separate preparations of abacavir, lamivudine and zidovudine should be administered to patients with reduced renal function (CrCl <50 mL/min). Hepatic Impairment: This drugs is contraindicated for use in hepatically impaired patients. Administration: Trizivir can be taken with or without food.
Contraindication ::
Hypersensitivity. Hepatic impairment, abnormally low neutrophil counts (<0.75 x 10 9/L) or abnormally low Hb levels (<7.5 g/dL or 4.65 mmol/L). Patient <40 kg, CrCl <50 mL/min.
Drug Precautions ::
Use of abacavir in patients known to carry HLA B*5701 allele is not recommended. Screening should be performed before initiating treatment or prior to reinitiation in patients w/ unknown HLA B*5701 status who have previously tolerated abacavir. Hypersensitivity reaction. Risk of lactic acidosis & hepatomegaly w/ steatosis in patients (esp obese women w/ hepatomegaly), pancreatitis, hepatitis or other known risk factors for hepatic disease. Due to haematological AR, monitor haematological parameters during treatment esp in patients w/ poor bone marrow reserve or advanced HIV disease. Discontinue immediately if pancreatitis is suspected. Co-infection w/ HBV or HCV. Immune reconstitution syndrome, opportunistic infections, transmission of infection, MI. Elderly. Pregnancy & lactation.
Drug Side Effects ::
Hypersensitivity reactions (discontinue immediately & do not rechallenge), GI disturbances, anorexia, headache, insomnia, muscle disorders, myalgia, cough, rash, alopecia, fever, malaise, fatigue, severe hepatomegaly w/ steatosis & lactic acidosis.
Pregnancy category ::
3
Drug Mode of Action ::
Abacavir, lamivudine and zidovudine are all nucleoside reverse transcriptase inhibitors. Converted to their respective active triphosphate form, they act synergistically to reduce viral resistance and inhibit reverse transcriptase via DNA chain termination.
Drug Interactions ::
Abacavir: Alcohol may cause decreased elimination of abacavir. Lactic acidosis with nucleoside analogues concomitantly. Decreased serum concentrations of methadone. Zidovudine: acyclovir and valacyclovir may increase CNS depression. Increased risk of haematologic toxicity with ganciclovir, valganciclovir, dapsone, doxorubicin, vincristine and vinblastine. Doxorubicin may reduce phophorylation; fluconazole may increase levels/effects; increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of pancreatitis and lactic acidosis). Methadone may increase effects/levels. Increased risk of myalgia, malaise and/or fever, maculopapular rash and effects/levels with probenecid. Stavudine may decrease antiviral activity; valproic acid may increase plasma levels (AUC increased by 80%). Lamivudine: Increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of mitochondrial toxicity, pancreatitis and lactic acidosis). Ganciclovir and valganciclovir may increase effects and toxicity; sulfamethoxazole/trimethoprim may increase AUC and decrease clearance (increasing levels and effects).